l e t t e r s Leber congenital amaurosis (LCA) is an infantile-onset form of inherited retinal degeneration characterized by severe vision loss 1,2 . Two-thirds of LCA cases are caused by mutations in 17 known disease-associated genes 3 (Retinal Information Network (RetNet)). Using exome sequencing we identified a homozygous missense mutation (c.25G>A, p.Val9Met) in NMNAT1 that is likely to be disease causing in two siblings of a consanguineous Pakistani kindred affected by LCA. This mutation segregated with disease in the kindred, including in three other children with LCA. NMNAT1 resides in the previously identified LCA9 locus and encodes the nuclear isoform of nicotinamide mononucleotide adenylyltransferase, a rate-limiting enzyme in nicotinamide adenine dinucleotide (NAD + ) biosynthesis 4, 5 . Functional studies showed that the p.Val9Met alteration decreased NMNAT1 enzyme activity. Sequencing NMNAT1 in 284 unrelated families with LCA identified 14 rare mutations in 13 additional affected individuals. These results are the first to link an NMNAT isoform to disease in humans and indicate that NMNAT1 mutations cause LCA.
Inherited retinal diseases, such as LCA, represent a heterogeneous group of early-onset blindness disorders that are characterized by progressive dysfunction and death of the rod and cone retinal photoreceptor cells 6 . Despite the identification so far of more than 180 different inherited retinal disease-associated genes, the genetic etiology remains uncertain in 40-50% of individuals with inherited retinal disease 7 (RetNet). Additional loci have been identified at which disease-associated genes have not yet been identified, such as the LCA9 locus mapped to chromosome 1p36 (ref. 4) . Identifying the genetic basis of inherited retinal diseases is essential to guide the development of potential therapies, as highlighted by the recent success of clinical gene therapy trials for RPE65-related LCA [8] [9] [10] [11] [12] . Here, we used whole-exome sequencing in a large consanguineous Pakistani family, including five children affected with LCA who did not have mutations in known LCA-causing genes.
Two Pakistani siblings, an 11-year-old girl and her 3-year-old brother ( Fig. 1a , family 047, subjects IV-1 and IV-3, respectively), initially came to the Ophthalmology-Genetics Clinic at the Children's Hospital of Philadelphia for evaluation of LCA because of severe vision impairment, congenital nystagmus and no detectable (<10 µV) retinal function by full-field electroretinography (ERG) testing in early infancy (see Supplementary Note for additional clinical details). Both children also had global developmental delay, nonverbal autism with stereotypies, hypotonia with joint hypermobility and dysmorphic facies. Severe-to-profound bilateral sensorineural hearing loss was present in the 11-year-old proband (IV-1) and in her 8-year-old brother (IV-2), who had a normal eye exam and normal development but exhibited clinical features consistent with mucolipidosis (Supplementary Note).
l e t t e r s
Their parents were first cousins who were visually and developmentally normal ( Fig. 1a , subjects III-4 and III-5). Notably, the parents' siblings had married one another ( Fig. 1a , subjects III-3 and III-6) and together had two children with similar vision and nonverbal autism phenotypes as the proband (subjects IV-7 and IV-8) and one child with isolated LCA (IV-6). Clinical genetic diagnostic testing identified a homozygous mutation in GJB2 (c.71G>A, p.Trp24*) as the cause of sensorineural hearing loss in subject IV-1, but no mutation was identified in any of the known LCA-causing genes (Supplementary Note). Additional sequencing analyses verified that the homozygous mutation encoding p.Trp24* in GJB2 segregated with the hearing loss phenotype in the larger kindred ( Fig. 1a) .
To search for the genetic cause of LCA in this family, we performed whole-exome sequencing of the nuclear family of the 11-year-old proband ( Fig. 1a , subjects IV-1, IV-2, IV-3, III-4 and III-5). Given known consanguinity, a homozygous mutation of biparental inheritance that was shared by both affected children but not by their sibling with normal visual acuity was postulated to be the most likely mode of LCA inheritance. We identified a total of 113 nonsynonymous variants in 86 genes that met these criteria ( Supplementary  Fig. 1 ). Four of these variants were rare or novel according to dbSNP 132, 1000 Genomes Project data and National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) data 13, 14 .
The genes harboring these four variants had known retinal expression, which was determined from mouse retina RNA sequencing (RNA-seq) analyses 15 . Only one of these variants was predicted to damage protein function by SIFT, PolyPhen-2 and other programs: c.25G>A (p.Val9Met) in NMNAT1 (refs. 16-20) (NM_022787). Sanger sequencing of the c.25G>A variant in NMNAT1 validated its segregation with the LCA phenotype in the original nuclear kindred and in the proband's similarly affected cousins, including the one with isolated LCA (Fig. 1a,b ). Only the mutant M1 allele encoding p.Val9Met NMNAT1 was detected in the five children with LCA in generation IV, whereas the four unaffected parents of these children in generation III carry both the mutant and wild-type alleles, and their three children with normal vision harbor only the wild-type allele (Fig. 1b) . The p.Val9Met variant was not present in 501 controls or in any public databases 13, 14 .
No clearly pathogenic mutations were identified that were likely to be the cause of developmental delay, nonverbal autism, hypotonia and dysmorphic facies in family members IV-1, IV-3, IV-7 and IV-8. These presentations likely have a separate genetic etiology from that of LCA and deafness in this family, as individual IV-6 has LCA alone, individual IV-2 has deafness alone and additional NMNAT1 mutations were identified in individuals with non-syndromic LCA, as described below. 
Family 053 
To determine whether NMNAT1 mutations cause LCA in other families, we sequenced NMNAT1 in 56 unrelated probands with LCA evaluated at The Children's Hospital of Philadelphia (CHOP) and the Massachusetts Eye and Ear Infirmary (MEEI). We found rare compound heterozygous mutations in NMNAT1 that segregated with disease in family 007, in which the proband was a 5-year-old girl with isolated LCA and there was no family history of the disease ( Fig. 1c and Table 1 ). We also identified compound heterozygous variants in NMNAT1 that segregated with disease in family 053, in which the proband was a 20-year-old man with LCA ( Fig. 1d and Table 1 ). The four NMNAT1 variants identified in these subjects were not identified in 501 control samples.
To investigate the frequency of NMNAT1 mutations in LCA, we screened additional populations of affected individuals from varying ancestry groups. This analysis included 228 additional probands ascertained at Institut de la Vision in Paris, LVPEI in India and University College London (UCL). These analyses identified homozygous or compound heterozygous mutations in NMNAT1 in 11 additional families with LCA ( Table 1 and Supplementary Fig. 2 ). All of the mutations detected are rare, and all, with the exception of one encoding the p.Glu257Lys variant, were predicted to be damaging by PolyPhen-2 and/or SIFT ( Table 1) . None of the NMNAT1 variants identified in these subjects were identified by Sanger sequencing in 501 control samples. Review of available clinical information for individuals in whom NMNAT1 mutations were identified as the cause of LCA (Supplementary Note) indicated that the majority have atrophic macular lesions (Fig. 2) .
NMNAT1 encodes a rate-limiting enzyme that generates NAD + , both in a biosynthetic pathway from nicotinic acid mononucleotide (NaMN) and in a salvage pathway from nicotinamide mononucleotide (NMN) ( Supplementary Fig. 3 ) 21 . Three functionally nonredundant mammalian NMNAT isoforms encoded by different genes have been identified within distinct cellular compartments, with NMNAT1, NMNAT2 and NMNAT3 localizing to the nucleus, Golgi complex and mitochondria, respectively 5, 22 . The mitochondrial isoform, NMNAT3, regenerates NAD + for cellular energetics, whereas NMNAT1 is involved in the nuclear NAD + homeostasis that is necessary for both DNA metabolism and cell signaling 5 . Of interest, Nmnat1 is the principal component of the mouse Wallerian degeneration fusion protein (Wld s ), which also includes a 70-residue N-terminal sequence from the Ube4b multiubiquitination factor, and has been shown to have neuroprotective activity 23 . Homozygous Nmnat1-knockout mice are embryonic lethal, whereas heterozygous Nmnat1-knockout mice have normal development 24 . Loss of nmnat in Drosophila melanogaster photoreceptors leads to photoreceptor cell degeneration 25 . The p.Glu257Lys variant in NMNAT1 was detected in a total of six families. Although this variant is sufficiently rare to be associated with LCA (estimated prevalence of 1 in 30,000) 33 according to ESP data (13/10,745 = 0.12%), it is not predicted to damage protein function by PolyPhen-2 or SIFT. However, it is known that these prediction programs have significant false positive and negative rates and frequently do not agree with one another 34, 35 . We therefore employed Fisher's exact test to estimate the probability that the p.Glu257Lys variant causes disease. This analysis showed that the allele frequency for the p.Glu257Lys variant was significantly higher in the LCA cases (6/568 chromosomes = 1.056%) compared to both our controls (0/1,002 chromosomes = 0%; P = 0.002) and ESP samples (13/10,758 chromosomes = 0.121%; P = 0.0002), which is consistent with a high likelihood that this variant is pathogenic.
npg l e t t e r s
We assessed the potential deleterious effects of the novel missense variants p.Val9Met, p.Arg66Trp and p.Arg237Cys on the NMNAT1 protein. These altered residues are located in conserved regions of the protein (Supplementary Fig. 4 ) and are predicted to damage NMNAT1 protein structure and stability by several prediction programs 26, 27 . All three of these mutant proteins showed correct nuclear localization and normal expression levels following expression of recombinant NMNAT1 proteins in heterologous cells (Supplementary Fig. 5a,b) . In addition, the p.Val9Met mutant correctly localized to the nucleus of a fibroblast cell line obtained from the proband with LCA in family 047 ( Fig. 1a, subject IV-1, and Supplementary Fig. 5c) 22 .
Given the normal nuclear localization and expression of the mutant NMNAT1 proteins, we postulated that the deleterious effect of the p.Val9Met, p.Arg66Trp and p.Arg237Cys variants might be on NMNAT1 enzymatic function. We therefore measured the NAD + biosynthetic activity of wild-type and mutant purified recombinant NMNAT1 proteins (Fig. 3a) . Despite variability in enzyme rates between experimental days, the protein activity of the NMNAT1 p.Val9Met variant was reproducibly and significantly lower than that of wild-type protein on the same day (63.4% median reduction, interquartile range 31.4-88.7; Wilcoxon rank-sum test P = 0.0015). The enzyme activity of the p.Arg66Trp mutant was also significantly lower (99.5% median reduction, interquartile range 0.01-0.11; Wilcoxon rank-sum test P = 0.0014), although we were not able to achieve effective purification of the Flag-tagged version of this mutant (Supplementary Fig. 6) , despite its clearly normal expression and nuclear localization in CHO and mIMCD3 cells (Supplementary Fig. 5) . The enzyme activity of the p.Arg237Cys mutant was only marginally lower than that of wild-type protein (18.9% reduction, interquartile range 41.1-90.1; Wilcoxon rank-sum test P = 0.034) (Fig. 3a) , raising the question of how this mutation causes disease. It has been observed that NMNAT1 forms functional homo-oligomers and that amino acids 234-238 participate in these protein interactions 5 . To evaluate whether the pathogenic effect of the p.Arg237Cys alteration could be related to its location in a region of NMNAT1 that is involved in protein multimerization, we measured NMNAT1 activity in recombinant protein purified from cells cotransfected with constructs for both the p.Arg66Trp and p.Arg237Cys variants that were identified in family 007. We observed notably lower enzyme activity (18% of wild-type control rate; data not shown) in the combined protein preparation. Additional studies using extracts from the fibroblast cells of the proband with the p.Val9Met alteration (Fig. 1a , subject IV-1) showed 73% lower total cellular NMNAT enzyme activity (two-tailed t test P = 0.016) relative to wild-type control (Fig. 3b) . These data suggest that the pathogenic effects of these mutations are related, at least in part, to significantly reduced NMNAT1 enzyme activity. It will be of interest to investigate the function of the mutant NMNAT1 proteins in retinal cells, given the isolated retinal phenotype of LCA.
The total NAD + concentration of human cells has many contributing determinants 21, 28 . We measured NAD + in the fibroblast cell line from the proband with LCA ( Fig. 1a , subject IV-1) to determine whether the p.Val9Met alteration in the nuclear-localized NMNAT1 protein significantly affected total cellular NAD + content. Fibroblasts from the proband with LCA had 16% less NAD + content than wildtype controls, although this difference was not statistically significant (two-tailed t test P = 0.067; Fig. 3c ). These data suggest that the reduction in NMNAT1 enzyme activity caused by the p.Val9Met alteration may be sufficient to affect total cellular NAD + content.
Cellular NAD + concentrations can be directly increased by nicotinic acid, which requires NMNAT activity for its conversion to NAD + (Supplementary Fig. 3) 29 . We therefore asked whether cellular NAD + concentration in the fibroblasts expressing the NMNAT1 p.Val9Met mutant (from subject IV-1) was altered by exposure to 10 mM nicotinic acid for 24 h. Notably, whereas nicotinic acid significantly increased the total cellular NAD + content by 53% in control cells (two-tailed t test P = 0.021), it had no effect on NAD + content in the fibroblasts from the proband with LCA ( Fig. 3c ; two-tailed t test P > 0.05). The inability of nicotinic acid to increase the NAD+ content in NMNAT1 p.Val9Met mutant fibroblasts provides further evidence that they have a substantial deficiency in cellular NMNAT enzymatic activity.
In summary, we report here the first instance of disease association with an NMNAT isoform 5 . NMNAT1 mutations cause LCA and are the likely pathogenic basis for disease previously linked to the LCA9 locus, although the family in which disease was originally linked to this locus was not available for analysis in this study 4 (C. Toomes and C. Inglehearn, personal communication). Through exome sequencing in a consanguineous Pakistani kindred with LCA and subsequent Sanger sequencing of NMNAT1 in 284 additional unrelated probands with LCA, we identified mutations in 14 unrelated (a) The NAD + biosynthetic activities of wild-type (WT) and mutant purified recombinant NMNAT1 proteins were measured. Box plots show activity measurements from replicate protein preparations that were independently generated and measured. The length of the box represents the 25 th to 75 th interquartile range, the interior horizontal line represents the median, the interior cross represents the mean, and vertical lines issuing from the box extend to the minimum and maximum values of the analysis variable. The p.Trp169Ala mutant had no NMNAT1 enzyme activity (n = 6; P = 0.0014), as was previously reported 32 . The p.Val9Met mutant had significantly lower enzyme activity (37% of wild-type NMNAT1 activity) (n = 7; P = 0.0015). The p.Arg237Cys mutant had 81% of wild-type NMNAT1 activity (n = 6; P = 0.034). The p.Arg66Trp mutant had no NMNAT1 enzyme activity (n = 6; P = 0.0014). *P < 0.05; **P < 0.01; determined by non-parametric Wilcoxon rank-sum test. (b) Total cellular NMNAT enzyme activity was measured in whole-cell extracts of fibroblasts from a healthy control and a proband with LCA (subject IV-1 from family 047) who was homozygous for the p.Val9Met NMNAT1 variant. The mutant cells had 27% of the total cellular NMNAT NAD + synthetic activity of control cells (two-tailed t test P = 0.016; n = 6 for wild-type, n = 5 for mutant cells). (c) Cellular NAD + levels. Total cellular NAD + content was quantified by HPLC in the same control and mutant fibroblasts as in b at baseline and after exposure to 10 mM nicotinic acid (NA) for 24 h. NAD + content in fibroblasts from the proband with LCA was decreased by 16% relative to that in wild-type cells (P = 0.067). Nicotinic acid exposure significantly increased NAD + content in control cells but had no effect on NAD + content in the mutant cells. n = 7 for both cell lines without treatment, n = 6 for control cells exposed to nicotinic acid, and n = 4 for mutant cells exposed to nicotinic acid. In b and c, data are shown as the mean with standard error; *P < 0.05. . This work suggests that mutations in NMNAT1 are a relatively common cause of LCA 3 . However, because the cohorts of individuals used for these studies are enriched for subjects without mutations in known LCA-causing genes, the proportion of all LCA cases caused by NMNAT1 mutations is likely to be overestimated by these data. The identification of NMNAT1 as an LCA-causing gene raises the intriguing question of how mutations in a widely expressed NAD + biosynthetic protein lead to a retina-specific phenotype. The data presented suggest that the retinal degeneration phenotype observed in individuals with NMNAT1 mutations results from decreased NAD + biosynthetic activity. This hypothesis is consistent with findings from studies of the Wld s protein in mice, which showed that the neuroprotective effect of the Wld s protein required both the Ube4b component and an enzymatically active NMNAT1 portion of the chimeric protein 30 . However, it seems that, in some systems, such as Drosophila, nmnat alone has a neuroprotective role that may be independent of its NAD + biosynthetic activity 25, 31 . Thus, it remains to be determined whether retinal degeneration caused by mutations in NMNAT1 results primarily from the loss of a potentially novel neuroprotective effect of NMNAT1 or a previously unappreciated role of NAD + -mediated signaling in retinal health and disease. In either case, NMNAT1 mutations represent a new pathophysiological cause of LCA, further underscoring the genetic heterogeneity of inherited retinal diseases 3, 6 . We postulate that pharmacologic and/or genetic therapies directed at restoring cellular NAD + homeostasis in retinal cells may offer a therapeutic strategy for NMNAT1-related LCA.
URLs. Exome Variant Server, NHLBI Exome Sequencing Project (ESP), http://evs.gs.washington.edu/EVS/; RetNet Retinal Information Network, https://sph.uth.tmc.edu/retnet/; 1000 Genomes Project, http://www.1000genomes.org/; UCSC Genome Browser, http:// genome.ucsc.edu/.
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Note: Supplementary information is available in the online version of the paper.
HPLC conditions for analyses of NAD + . Separation of the oxidized dinucleotides was carried out on a C18 column (5 µm, 4.6 × 250 mm, Adsorbosphere XL C18 90Å) preceded by a guard column at 40 °C. Flow rate was set at 0.5 ml/min. The mobile phase was initially 100% of mobile phase A (0.1 M sodium phosphate buffer (pH 6.0) containing 3.75% methanol). The methanol concentration was linearly increased with mobile phase B (0.1 M sodium phosphate buffer (pH 6.0) containing 30% methanol), increasing to 50% over 15 min. The column was washed after each separation by increasing mobile phase B to 100% for 5 min. UV absorbance was monitored at 260 and 340 nm with Shimadzu SPD-M20A. Pertinent peak areas were integrated using LabSolution software from Shimadzu and were quantified using standard curves.
Statistical analyses. For comparison of the activity rates of purified recombinant NMNAT1 proteins with that of wild-type protein, rates were normalized by the mean rate of the wild-type protein analyzed on the same day to account for variation in the absolute enzyme activity rates on different analysis dates. The significance of differences between groups was evaluated using a nonparametric Wilcoxon rank-sum test in SAS 4.3 because of skewness observed in the data and small sample size. For measurements of cellular NMNAT activity and NAD + concentrations, statistical comparisons between groups were performed using Student's two-tailed t-tests.
